TKI and checkpoint inhibitor combinations for kidney cancer: the IMmotion151 trial

The current standard of care for frontline kidney cancer is tyrosine kinase inhibitor (TKI) treatment. Now there are a host of promising immune checkpoint inhibitors in trials for this indication, eit... Author: VJOncology Added: 02/19/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts